DarioHealth Announces 20-to-1 Reverse Stock Split
DarioHealth (NASDAQ: DRIO), a digital health market leader, has announced a 20-for-1 reverse stock split effective August 28, 2025. The company's outstanding common stock will be reduced from 47,996,572 to approximately 2,399,829 shares.
The split was approved by DRIO's board of directors following stockholder authorization at the July 23, 2025 Annual Meeting. Trading will continue under the "DRIO" symbol but with a new CUSIP Number (23725P 308). The company's authorized shares remain at 400,000,000, and fractional shares will be rounded up to the nearest whole share per stockholder.
The reverse split will not materially affect stockholders' ownership percentages or voting power, and all options, convertible securities, restricted stocks, and warrants will be appropriately adjusted.
DarioHealth (NASDAQ: DRIO), leader nel settore della salute digitale, ha annunciato un reverse split 20-in-1 con efficacia dal 28 agosto 2025. Le azioni ordinarie in circolazione passeranno da 47.996.572 a circa 2.399.829 azioni.
La riduzione è stata approvata dal consiglio di amministrazione di DRIO a seguito dell'autorizzazione degli azionisti nella Assemblea Annuale del 23 luglio 2025. Le azioni continueranno a essere negoziate con il simbolo "DRIO", ma con un nuovo CUSIP (23725P 308). Le azioni autorizzate restano 400.000.000; le frazioni di azione saranno arrotondate per eccesso alla più vicina azione intera per ciascun azionista.
Il reverse split non altererà materialmente le percentuali di proprietà né i diritti di voto degli azionisti e tutte le opzioni, i titoli convertibili, le azioni vincolate e i warrant saranno adeguati di conseguenza.
DarioHealth (NASDAQ: DRIO), líder en salud digital, ha anunciado una consolidación inversa de acciones 20 a 1 que entra en vigencia el 28 de agosto de 2025. Las acciones ordinarias en circulación se reducirán de 47.996.572 a aproximadamente 2.399.829 acciones.
La operación fue aprobada por el consejo de administración de DRIO tras la autorización de los accionistas en la Junta Anual del 23 de julio de 2025. Las acciones seguirán cotizando con el símbolo "DRIO", pero con un nuevo CUSIP (23725P 308). Las acciones autorizadas permanecen en 400.000.000; las fracciones de acción se redondearán al alza hasta la acción entera más cercana por accionista.
La consolidación inversa no afectará de forma material los porcentajes de propiedad ni el poder de voto de los accionistas, y todas las opciones, valores convertibles, acciones restringidas y warrants serán ajustados en consecuencia.
DarioHealth (NASDAQ: DRIO), 디지털 헬스 분야 선도기업이 2025년 8월 28일부로 20대1 주식 액면분할(역병합)을 시행한다고 발표했습니다. 발행 중인 보통주는 47,996,572주에서 약 2,399,829주로 줄어듭니다.
이번 역병합은 2025년 7월 23일 연례총회에서 주주 승인을 받은 후 DRIO 이사회가 승인했습니다. 거래는 "DRIO" 심볼로 계속되며 새로운 CUSIP 번호(23725P 308)가 부여됩니다. 승인된 발행주식 수는 400,000,000주로 유지되며, 주식 소수점은 주주별로 가장 가까운 정수 주식으로 올림됩니다.
역병합은 주주의 지분 비율이나 의결권에 실질적 영향을 미치지 않으며, 모든 옵션, 전환증권, 제한주 및 워런트는 적절히 조정됩니다.
DarioHealth (NASDAQ: DRIO), acteur majeur de la santé numérique, a annoncé une fusion d'actions inverse 20 pour 1 prenant effet le 28 août 2025. Les actions ordinaires en circulation seront réduites de 47 996 572 à environ 2 399 829 actions.
La décision a été approuvée par le conseil d'administration de DRIO suite à l'autorisation des actionnaires lors de l'Assemblée générale annuelle du 23 juillet 2025. Les titres continueront d'être cotés sous le symbole « DRIO », mais avec un nouveau CUSIP (23725P 308). Le nombre d'actions autorisées reste de 400 000 000 ; les fractions d'actions seront arrondies à la hausse à l'action entière la plus proche pour chaque actionnaire.
La fusion inverse n'affectera pas de manière significative les pourcentages de participation ni le pouvoir de vote des actionnaires, et toutes les options, titres convertibles, actions restreintes et bons de souscription seront ajustés en conséquence.
DarioHealth (NASDAQ: DRIO), ein führendes Unternehmen im Bereich Digital Health, hat eine Reverse Stock Split im Verhältnis 20 zu 1 bekanntgegeben, der am 28. August 2025 wirksam wird. Die ausstehenden Stammaktien werden von 47.996.572 auf etwa 2.399.829 Aktien reduziert.
Der Split wurde vom Vorstand von DRIO nach Zustimmung der Aktionäre auf der Jahreshauptversammlung am 23. Juli 2025 genehmigt. Der Handel läuft weiterhin unter dem Symbol "DRIO", jedoch mit einer neuen CUSIP-Nummer (23725P 308). Die genehmigten Aktien bleiben bei 400.000.000; Bruchteilsaktien werden je Aktionär auf die nächsthöhere ganze Aktie aufgerundet.
Der Reverse Split wird die Eigentumsanteile oder Stimmrechte der Aktionäre nicht wesentlich verändern, und alle Optionen, wandelbaren Wertpapiere, Restricted Stocks und Warrants werden entsprechend angepasst.
- Potential compliance with Nasdaq minimum bid price requirements
- No material impact on stockholders' ownership percentages or voting power
- Fractional shares will be rounded up, benefiting shareholders
- Significant reduction in outstanding shares may impact stock liquidity
- Could signal company's struggles to maintain stock price naturally
- May face market perception challenges associated with reverse splits
Insights
DarioHealth's 20:1 reverse split aims to boost share price while maintaining listing requirements, with no change to shareholder equity or company value.
DarioHealth's announcement of a 20-to-1 reverse stock split represents a significant corporate action that will consolidate the company's outstanding shares from 47,996,572 to approximately 2,399,829 while maintaining the same 400,000,000 authorized shares. This type of corporate restructuring is typically implemented when a company faces challenges maintaining minimum share price requirements for continued listing on exchanges like Nasdaq.
The mechanics of this split are straightforward: for every twenty shares currently held, shareholders will receive one share after August 28th. Importantly, this consolidation doesn't change the proportional ownership or voting rights of existing shareholders, as confirmed in the release. The company has also addressed practical concerns by rounding up fractional shares to the nearest whole share per stockholder, preventing shareholders from losing value due to fractional ownership.
What's notably absent from this announcement is any mention of the current share price or explicit reasoning behind the reverse split. However, reverse splits are commonly employed when share prices fall below exchange minimums (typically $1 for Nasdaq) for extended periods. This restructuring appears designed to boost the stock's per-share price proportionally by the 20:1 ratio, potentially bringing it back into compliance with listing requirements while making the shares more attractive to certain institutional investors who avoid low-priced stocks.
All outstanding securities including options, warrants, preferred stock, and restricted stock units will be proportionally adjusted to reflect the new share structure, ensuring no dilution of value across different security types. The fundamental economics and market capitalization of DarioHealth remain unchanged by this corporate action—it's purely a change in share structure, not underlying business performance or company value.
After giving effect to the reverse share split of the Company's Common Stock, each twenty (20) Common Stock will be combined into one (1) Common Stock, such that the Company's 47,996,572 Common Stock outstanding will be reduced to approximately 2,399,829 Common Stock outstanding (the "Reverse Stock Split"). The Reverse Stock Split has no impact on the Company authorized shares, which remains 400,000,000 shares of common stock. No fractional shares will be issued as a result of the Reverse Stock Split as any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per stockholder basis.
The Reverse Stock Split was approved by the Company's board of directors under authority granted by the Company's stockholders at the Company's 2025 Annual Meeting of Stockholders held on July 23, 2025.
The Reverse Stock Split will not impact any stockholder's percentage ownership of Dario or voting power, except for minimal effects resulting from the treatment of fractional shares.
All options, convertible securities including preferred stock, lock-up shares, restricted stocks (vested and unvested), restricted stock units and warrants of the Company outstanding prior to the Reverse Stock Split will be appropriately adjusted.
The Reverse Stock Split will not change the number of authorized shares of preferred stock, or the par value of common stock or preferred stock. After the Reverse Stock Split, the shares of the Company's Common Stock will have the same proportional voting rights and rights to dividends and distributions. VStock Transfer, LLC, will act as the exchange agent for the Reverse Stock Split. Please contact VStock Transfer, LLC for further information at (212) 828-8436.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the implementation of the Reverse Stock Split. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corp. Corporate Contacts:
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
DarioHealth Corp. Investor Relations Contact:
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-announces-20-to-1-reverse-stock-split-302537519.html
SOURCE DarioHealth Corp.
FAQ
When will DarioHealth's (DRIO) 20-to-1 reverse stock split take effect?
How many shares will DarioHealth (DRIO) have outstanding after the reverse split?
Will DarioHealth's (DRIO) reverse stock split affect shareholders' ownership percentage?
What happens to fractional shares in DarioHealth's (DRIO) reverse split?
How will DarioHealth's (DRIO) reverse split affect existing options and warrants?
